PTC Therapeutics (PTCT) has an average broker rating of 2.67, which is interpreted as a Hold, as rated by 6 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 5 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
PTC Therapeutics (PTCT) : Average target price received by PTC Therapeutics (PTCT) is $11.4 with an expected standard deviation of $5.03. The most aggressive target on the stock is $20, whereas the most downbeat target is $7. 5 financial analysts are currently covering the stock.
Company shares have received an average consensus rating of Hold for the current week Also, In a research note released to the investors, Citigroup maintains its rating on PTC Therapeutics (NASDAQ:PTCT).The analysts at the brokerage house have a current rating of Neutral on the shares. In a recent information released to the investors, Citigroup raises the new price target from $8 per share to $9 per share. The rating by the firm was issued on August 8, 2016.
PTC Therapeutics (NASDAQ:PTCT): The stock opened at $8.05 and touched an intraday high of $8.42 on Wednesday. During the day, the stock corrected to an intraday low of $8.0099, however, the bulls stepped in and pushed the price higher to close in the green at $8.18 with a gain of 2.12% for the day. The total traded volume for the day was 615,504. The stock had closed at $8.01 in the previous trading session.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that target post-transcriptional control processes. The Companys internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Companys lead product, Translarna (ataluren), is used for the treatment of genetic disorders due to a nonsense mutation in ambulatory patients aged five years and older. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF).